One day late. Nine figures short.
Thats the headline lesson from a recent patent dispute in the pharmaceutical worldone where timing wasnt just important, it was existential. In a market built on years of R&D, regulatory timelines, and blockbuster …

One day late. Nine figures short.
Thats the headline lesson from a recent patent dispute in the pharmaceutical worldone where timing wasnt just important, it was existential. In a market built on years of R&D, regulatory timelines, and blockbuster …

Most people dont lose on drug launches because they missed the science. They miss because they missed the timer.
In generics and biosimilars, timing is the competitive edgeand one phrase keeps showing up for teams that consistently spot opportunities e…

Stable drug patents arent stable at all.
For years, the market treated pharmaceutical patents like weather forecasts: mostly predictable, with changes only coming slowlyone court decision, one filing, one settlement at a time. But the piece from Drug…

Drug Patent Watch argues that stable drug patents are a mythbecause in the real world, IPRs (Inter Partes Reviews) can flip the market overnight. Heres why that matters for investors, innovators, and anyone pricing risk in healthcare.
The story we tell…

Most Paragraph IV strategies fail for a reason people rarely admit: they assume the market will behave like the playbook.
But markets dont move. They adaptoften with surgical precision. In a world where brand companies dont just defend patents, they re…

The First-Filers Trap: Why 180-Day Exclusivity Fails Without a Supply-Chain Moat
Theres a comforting myth in generic and biosimilar strategy: file first, win big.
Companies spend years building regulatory dossiers around one lever180-day exclusivitythe…

Stop chasing blockbusters. The high-margin world of unloved orphan patents is where the real profit hides.
For years, the drug strategy playbook has been simple: find the next blockbuster, wait for the curve, monetize the peak. But blockbuster economic…

Your regulatory team doesnt have a patent problem. It has a timing problem.
Thats the uncomfortable truth hiding behind most late-stage surprises in pharma. A regulator-facing CMC package can be flawless, a submission can be perfectly compliant, and an…

The late pivot is expensive. Drug patent intelligence belongs at the start of R&Dnot after your team has already committed.
Most R&D failures dont start with bad science. They start with momentum.
A program team signs off on a mechanism, a form…